CLINICAL TRIAL: REGIMENS/TREATMENT SWITCHING STRATEGIES IN HIV CHILDREN ACTG390

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 ACTG390这项研究将评估两种不同的抗艾滋病毒药物治疗组合，并将使用从一种治疗组合切换到另一种治疗组合的两种计划中的一种。一项计划将在血液中艾滋病毒含量(病毒载量)为1,000份时切换治疗组合，另一项计划将在血液中HIV数量为30,000份时切换治疗方案。这项研究将评估在四年的治疗中，这两个转换计划中的任何一个在益处上是否存在差异。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ACTG390 This study will evaluate two different treatment combinations of anti-HIV drugs and will use one of two plans for switching from one to the other treatment combinations. One plan will switch treatment combination when the amount of HIV in the bloodstream (viral load) is 1,000 copies and the other plan will switch treatment when the amount of HIV in the bloodstream is 30,000 copies. The study will evaluate if there is a difference in benefit for either of the two switching plans in a four year treatment.